LNTH
Lantheus Holdings, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
100.32
close · 2026-10-29
value
26
cheaper than peers26
quality
81
stronger fundamentals81
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| EV to EBITDA | 16.73× | 43 |
| forward P/E | 15.73× | 36 |
| price to sales | 4.23× | 31 |
| price to book | 4.99× | 30 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 25.8% | 81 |
| return on equity | 22.2% | 78 |
| debt to equity | 43.5% | 70 |
| revenue growth | 2.7% | 36 |
4 of 4 measures available
Facts
| market cap | $7B |
| free cash flow | $421.7M |
| employees | 1,193 |
| first trade | 2015-06-25 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 3.41 | 4.36 | 4.65 | 0.40 |
| free cash flow | $348.6M | $465.1M | $258.7M | $263.4M |
| net income | $233.6M | $312.4M | $326.7M | $28.1M |
| revenue | $1.54B | $1.53B | $1.30B | $935.1M |
| unusual items | -$5.4M | -$35.8M | $46.8M | -$4.9M |